Cyramza Ramicirumab

 Cyramza (Ramicirumab)

• Brand name: Cyramza   
• Active Ingeridents (Generic Name) : Ramicirumab
• Company Name: Lilly
• Package: Vial
• Strength :  500mg / 50ml

Indication:

It is used in the Treatment of advanced gastric cancer or gastro-esophageal junction adenocarcinoma. Non-small cell Lung cancer.  Metastatic Colorectal cancer.

Mechanism of action:

Cyramza (Ramicirumab) is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, Cyramza (Ramicirumab) prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells.

Dosage & Administration:

Side effects:

Diarrhea, headache, nausea, vomiting, mouth sores, or weakness may occur. Injection reactions such as shaking, back pain/spasms, chest tightness, chills, flushing, rapid heartbeat, dizziness, or skin tingling/burning may also occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.

Precaution:

Before receiving Cyramza (Ramicirumab), tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Store: Cyramza (Ramicirumab) is handled and stored by a health care provider. You will not store it at home. Keep all medicines out of the reach of children and away from pets.

Specification